The Potential Return on Public Investment in Detecting Adverse Drug Effects
- 1 June 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Medical Care
- Vol. 55 (6) , 545-551
Abstract
Background: Many countries lack fully functional pharmacovigilance programs, and public budgets allocated to pharmacovigilance in industrialized countries remain low due to resource constraints and competing priorities. Objective: Using 3 case examples, we sought to estimate the public health and economic benefits resulting from public investment in active pharmacovigilance programs to detect adverse drug effects. Research Design: We assessed 3 examples in which early signals of safety hazards were not adequately recognized, resulting in continued exposure of a large number of patients to these drugs when safer and effective alternative treatments were available. The drug examples studied were rofecoxib, cerivastatin, and troglitazone. Using an individual patient simulation model and the health care system perspective, we estimated the potential costs that could have been averted by early systematic detection of safety hazards through the implementation of active surveillance programs. Results: We found that earlier drug withdrawal made possible by active safety surveillance would most likely have resulted in savings in direct medical costs of $773–$884 million for rofecoxib, $3–$10 million for cerivastatin, and $38–$63 million for troglitazone in the United States through the prevention of adverse events. By contrast, the yearly public investment in Food and Drug Administration initiated population-based pharmacovigilance activities in the United States is about $42.5 million at present. Conclusion: These examples illustrate a critical and economically justifiable role for active adverse effect surveillance in protecting the health of the public.Keywords
This publication has 27 references indexed in Scilit:
- Active Safety Monitoring of New Medical Products Using Electronic Healthcare DataEpidemiology, 2012
- Pharmacovigilance Activities in 55 Low- and Middle-Income CountriesDrug Safety, 2010
- One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims databaseCurrent Medical Research and Opinion, 2008
- In Defense of Pharmacoepidemiology — Embracing the Yin and Yang of Drug ResearchNew England Journal of Medicine, 2007
- Risk of myocardial infarction associated with selective COX‐2 inhibitors: Meta‐analysis of randomised controlled trialsPharmacoepidemiology and Drug Safety, 2007
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Coxibs, science, and the public trust.Archives of internal medicine (1960), 2005
- Rofecoxib for rheumatoid arthritisCochrane Database of Systematic Reviews, 2005
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapyPharmacoepidemiology and Drug Safety, 2004